Accepted for/Published in: JMIR Public Health and Surveillance
Date Submitted: Feb 20, 2024
Open Peer Review Period: Feb 22, 2024 - Apr 18, 2024
Date Accepted: Jun 17, 2024
(closed for review but you can still tweet)
Illicit Cannabis Use to Self-Treat Chronic Health Conditions: A Cross-Sectional Study from the United Kingdom
ABSTRACT
Background:
In 2019, it was estimated that approximately 1.4 million adults in the United Kingdom (UK) purchase illicit cannabis to self-treat chronic physical and mental health conditions. This analysis was conducted following the rescheduling of cannabis-based medicinal products (CBMPs) in the UK, but before the first specialist clinics had started treating patients.
Objective:
The aim of this study was to assess the prevalence of illicit cannabis consumption to treat a medically diagnosed condition, following the introduction of specialist clinics who could prescribe legal CBMPs in the UK.
Methods:
Adults over the age of 18 in the UK were invited to participate in a cross-sectional survey though YouGov® between 22nd and 29th September 2022. A series of questions were asked about respondents’ medical diagnoses, illicit cannabis use, cost of purchasing illicit cannabis per month, and basic demographics. The responding sample was weighted to generate a sample representative of the adult population of the UK. Modelling of population size was conducted based on an adult (≥ 18 years) population of 53,369,083 according to 2021 national census data.
Results:
There were 10,965 respondents to the questionnaire, to which weighting was applied. 5,700 (51.98%) respondents indicated that they were affected by a chronic health condition. The most reported condition was anxiety (n = 1588; 14.48%). Of those suffering with health conditions, 364 (6.38%) purchased illicit cannabis to self-treat health conditions. 1,770,627 (95% confidence interval: 1,073,791–2,467,001) individuals were modelled to consume illicit cannabis for health conditions across the United Kingdom. On multivariable logistic regression, the following were associated with increased likelihood of reporting illicit cannabis use for health reasons: chronic pain, fibromyalgia, post-traumatic stress disorder, multiple sclerosis, other mental health disorders, male gender, younger age, living in London, being unemployed or not working for other reasons, and working part-time (p<0.050).
Conclusions:
This study highlights the scale of illicit cannabis use for health reasons in the UK and the potential barriers to accessing legally prescribed CBMPs. This is an important step in developing harm reduction policies to transition these individuals, where appropriate, to CBMPs. This is particularly true considering the potential risks from harmful contaminants of illicit cannabis and self-treating a medical condition without clinical oversight. Moreover, it emphasises the need for further funding of randomised controlled trials and the use of novel methodologies to determine the efficacy of CBMPs and their utility in common chronic conditions. Clinical Trial: N/A
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.